With a noticeable shift from small molecules to biologicals, it’s no surprise that The Philadelphia Business Journal reports that biopharma is having difficulty finding enough people to participate in clinical trials for the growing backlog of experimental therapeutics.  Further, the FDA is requiring higher enrollments.  Meanwhile, various hospitals are working to overhaul their clinical trial agreements.        MORE